GRI Bio (GRI) Stock Price, News & Analysis

Company Overview

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Key Stats

• Today's Range: $1.60 to $1.87
• 50-Day Range: $1.21 to $9.01
• 52-Week Range: $1.10 to $106.04
• Volume: 241,291 shs
• Average Volume: 281,127 shs
• Market Capitalization: $955,500.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $115.50
• Consensus Rating: Buy

GRI Bio Stock Analysis - MarketRank™

GRI Bio scored higher than 47% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

GRI Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

GRI Bio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for GRI Bio are expected to grow in the coming year, from ($3.04) to ($0.90) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GRI Bio is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GRI Bio is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GRI Bio has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

34.61% of the float of GRI Bio has been sold short.

Short Interest Ratio / Days to Cover

GRI Bio has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GRI Bio has recently increased by 281.79%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

GRI Bio does not currently pay a dividend.

Dividend Growth

GRI Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

34.61% of the float of GRI Bio has been sold short.

Short Interest Ratio / Days to Cover

GRI Bio has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GRI Bio has recently increased by 281.79%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

GRI Bio has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for GRI Bio this week, compared to 1 article on an average week.

Search Interest

5 people have searched for GRI on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GRI Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.13% of the stock of GRI Bio is held by insiders.

Percentage Held by Institutions

Only 33.95% of the stock of GRI Bio is held by institutions.

GRI Stock Analysis - Frequently Asked Questions

How have GRI shares performed this year?

GRI Bio's stock was trading at $14.0828 at the beginning of the year. Since then, GRI shares have decreased by 87.1% and is now trading at $1.82.
View the best growth stocks for 2025 here.

When did GRI Bio's stock split?

GRI Bio shares reverse split before market open on Monday, February 24th 2025. The 1-17 reverse split was announced on Wednesday, February 19th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

How do I buy shares of GRI Bio?

Shares of GRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GRI Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GRI Bio investors own include SoFi Technologies (SOFI), NuCana (NCNA), Caribou Biosciences (CRBU), Cardio Diagnostics (CDIO), Intrusion (INTZ), Lonestar Resources US (LONE) and Children's Place (PLCE).

Company Calendar

• Today: 4/26/2025
• Next Earnings (Estimated): 5/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GRI
• CIK: 1824293
• Web: www.vallon-pharma.com
• Phone: 267-607-8255
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $115.50
• High Stock Price Target: $221.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +6,246.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($11.56)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-13,040,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -289.05%
• Return on Assets: -165.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.10
• Quick Ratio: 3.10

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.22 per share
• Price / Book: 0.35

Miscellaneous

• Outstanding Shares: 525,000
• Free Float: 8,921,000
• Market Cap: $955,500.00
• Optionable: Not Optionable
• Beta: -1.72